ivermectin - versus control - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.50 [0.01, 25.20]< 10%1 study (1/-)63.4 %NAnot evaluable crucial-
new illness compatible with Covid-19 0.07 [0.03, 0.14]< 120%2 studies (2/-)100.0 %highnot evaluable lowimportant-

safety endpoints 00

serious adverse events 0.50 [0.01, 25.20]< 10%1 study (1/-)63.4 %NAnot evaluable important-
adverse events 11.52 [0.67, 197.97]< 10%1 study (1/-)4.8 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.